Blog Read the latest perspectives from our team of subject matter experts and others How Incyte Is Advancing Clinical Trial RepresentationClinical trial representation is more than just a regulatory requirement—it’s a critical component of accessible healthcare. Ensuring that trial participants reflect the real-world patient population leads to more effective… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research Drug DevelopmentPatient RepresentationHow Incyte Is Advancing Clinical Trial RepresentationClinical trial representation is more than just a regulatory requirement—it’s a critical component of accessible healthcare. Ensuring that trial participants reflect the real-world patient population leads to more effective… Continue reading → Read the articleyes KOL EngagementRedefining Medical Affairs Strategy with DataAs the role of Medical Affairs continues to evolve, data plays an increasingly critical role in shaping key opinion leader (KOL) engagement strategies, identifying care gaps, and ensuring equitable… Continue reading → Read the articleno Provider DataRibbon Health and H1: Merging Missions to Transform HealthcareOn January 8th, we celebrated an exciting milestone: Ribbon Health merged with H1! This union represents a significant leap toward achieving our shared vision of transforming healthcare by ensuring… Continue reading → Read the articleno Provider DataCEO Insights: Why Ribbon Health Matters to H1’s MissionToday we announced that H1 has come together with Ribbon Health. You can read more about it here in the official press release, but I also wanted to share… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentPatient RepresentationH1’s Predictions for Healthcare and Pharma in 2025Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationFDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing patient representation in clinical trials not only makes… Continue reading → Read the articleno1234›»
